Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment.
about
Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Waldenstrom macroglobulinemia ...... enetoclax or MK2206 treatment.
@en
type
label
Waldenstrom macroglobulinemia ...... enetoclax or MK2206 treatment.
@en
prefLabel
Waldenstrom macroglobulinemia ...... enetoclax or MK2206 treatment.
@en
P2093
P2860
P356
P1433
P1476
Waldenstrom macroglobulinemia ...... venetoclax or MK2206 treatment
@en
P2093
A Chanan-Khan
M Kuranz-Blake
S Ailawadhi
S M Paulus
P2860
P2888
P356
10.1038/BCJ.2017.40
P577
2017-05-26T00:00:00Z
P6179
1085594886